Cysteinyl leukotriene receptor CysLT1 as a novel therapeutic target for allergic rhinitis treatment.
BACKGROUND
Cysteinyl leukotrienes (cys-LTs) play an important role in allergic rhinitis because CysLT(1) receptor antagonists relieve the symptoms of allergic rhinitis.


OBJECTIVE
I overview the clinical pharmacology of CysLT(1) receptor antagonists and their potential role in patients with allergic rhinitis.


METHODS
I review the evidence regarding the release of cys-LTs and localization of CysLT(1) receptor on nasal mucosa, and evaluate the clinical efficacy of CysLT(1) receptor antagonist in allergic rhinitis.


CONCLUSIONS
Immunohistochemical studies show that in allergic rhinitis, the major target of CysLT(1) receptor antagonists are the vascular bed and infiltrated leukocytes such as mast cells, eosinophils and macrophages. CysLT(1) receptor antagonists provide a new opportunity for simultaneous management of allergic diseases of the upper and lower respiratory tract.
Shirasaki
Hideaki
H
Sapporo Medical University, Department of Otolaryngology, S-1 W-16, Chuo-ku, Sapporo, 060-8543, Japan. shira@sapmed.ac.jp
D016503:Drug Delivery Systems; D004804:Eosinophils / Q000378:metabolism; D006801:Humans; D008264:Macrophages / Q000378:metabolism; D008407:Mast Cells / Q000378:metabolism; D008565:Membrane Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009297:Nasal Mucosa / Q000378:metabolism; D018077:Receptors, Leukotriene / Q000378:metabolism; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000503:physiopathology; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000503:physiopathology
D008565:Membrane Proteins; D018077:Receptors, Leukotriene; C083169:leukotriene D4 receptor